Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients

Background: CA 15.3 is elevated in most patients with distant metastatic breast cancer who had prognostic information. The present study was performed to estimate predictive ability of CA 15.3 in assessment of symptomatic metastasis in patients with breast cancer. Materials and Methods: During five...

Full description

Bibliographic Details
Main Authors: Amir Bahrami-Ahmadi, Fariborz Makarian, Mohammad R Mortazavizadeh, Mohammad F Yazdi, Mehdi Chamani
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2012-01-01
Series:Journal of Research in Medical Sciences
Subjects:
Online Access:http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2012;volume=17;issue=9;spage=850;epage=854;aulast=Bahrami-Ahmadi
id doaj-798ac10e45d44af2a55cd3af03b6cedc
record_format Article
spelling doaj-798ac10e45d44af2a55cd3af03b6cedc2020-11-24T22:58:56ZengWolters Kluwer Medknow PublicationsJournal of Research in Medical Sciences1735-19951735-71362012-01-01179850854Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patientsAmir Bahrami-AhmadiFariborz MakarianMohammad R MortazavizadehMohammad F YazdiMehdi ChamaniBackground: CA 15.3 is elevated in most patients with distant metastatic breast cancer who had prognostic information. The present study was performed to estimate predictive ability of CA 15.3 in assessment of symptomatic metastasis in patients with breast cancer. Materials and Methods: During five years, 159 primary breast cancer patients were evaluated. A total of 2226 determination of serum CA 15.3 (14 per patient) were performed. We performed contemporary clinical examinations with CA 15.3 measurements at the time of diagnosis, end of chemotherapy, every three months in the first two years and every six months in the second two years of follow-up period. Imaging studies were performed if clinical or laboratory examinations (abnormal serum levels of CA 15.3) suspected symptomatic metastasis. Metastasis in participants was confirmed by imaging study in symptomatic patients. Results: There was no significant increase in CA 15.3 tumor markers during chemotherapy (P = 0.08). There was a significant relationship between CA 15.3 positive results and metastasis situation (P = 0.00). Mean of maximum CA 15.3 level in metastatic patients (52.72±27.09) was significantly higher than non-metastatic patients (27.58±13.46; P = 0.00). CA 15.3 abnormality (OR, 1.07; 95% CI: 1.04-1.11; P value, 0.01) and abnormal lymph nodes remained as predictor of metastasis (OR: 1.16; 95% CI: 1.05-1.28; P value < 0.0001). Conclusion: CA 15.3 is one of the predicting factors for symptomatic metastasis.http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2012;volume=17;issue=9;spage=850;epage=854;aulast=Bahrami-AhmadiBreast cancerCA 15.3metastasisprediction
collection DOAJ
language English
format Article
sources DOAJ
author Amir Bahrami-Ahmadi
Fariborz Makarian
Mohammad R Mortazavizadeh
Mohammad F Yazdi
Mehdi Chamani
spellingShingle Amir Bahrami-Ahmadi
Fariborz Makarian
Mohammad R Mortazavizadeh
Mohammad F Yazdi
Mehdi Chamani
Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients
Journal of Research in Medical Sciences
Breast cancer
CA 15.3
metastasis
prediction
author_facet Amir Bahrami-Ahmadi
Fariborz Makarian
Mohammad R Mortazavizadeh
Mohammad F Yazdi
Mehdi Chamani
author_sort Amir Bahrami-Ahmadi
title Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients
title_short Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients
title_full Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients
title_fullStr Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients
title_full_unstemmed Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients
title_sort symptomatic metastasis prediction with serial measurements of ca 15.3 in primary breast cancer patients
publisher Wolters Kluwer Medknow Publications
series Journal of Research in Medical Sciences
issn 1735-1995
1735-7136
publishDate 2012-01-01
description Background: CA 15.3 is elevated in most patients with distant metastatic breast cancer who had prognostic information. The present study was performed to estimate predictive ability of CA 15.3 in assessment of symptomatic metastasis in patients with breast cancer. Materials and Methods: During five years, 159 primary breast cancer patients were evaluated. A total of 2226 determination of serum CA 15.3 (14 per patient) were performed. We performed contemporary clinical examinations with CA 15.3 measurements at the time of diagnosis, end of chemotherapy, every three months in the first two years and every six months in the second two years of follow-up period. Imaging studies were performed if clinical or laboratory examinations (abnormal serum levels of CA 15.3) suspected symptomatic metastasis. Metastasis in participants was confirmed by imaging study in symptomatic patients. Results: There was no significant increase in CA 15.3 tumor markers during chemotherapy (P = 0.08). There was a significant relationship between CA 15.3 positive results and metastasis situation (P = 0.00). Mean of maximum CA 15.3 level in metastatic patients (52.72±27.09) was significantly higher than non-metastatic patients (27.58±13.46; P = 0.00). CA 15.3 abnormality (OR, 1.07; 95% CI: 1.04-1.11; P value, 0.01) and abnormal lymph nodes remained as predictor of metastasis (OR: 1.16; 95% CI: 1.05-1.28; P value < 0.0001). Conclusion: CA 15.3 is one of the predicting factors for symptomatic metastasis.
topic Breast cancer
CA 15.3
metastasis
prediction
url http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2012;volume=17;issue=9;spage=850;epage=854;aulast=Bahrami-Ahmadi
work_keys_str_mv AT amirbahramiahmadi symptomaticmetastasispredictionwithserialmeasurementsofca153inprimarybreastcancerpatients
AT fariborzmakarian symptomaticmetastasispredictionwithserialmeasurementsofca153inprimarybreastcancerpatients
AT mohammadrmortazavizadeh symptomaticmetastasispredictionwithserialmeasurementsofca153inprimarybreastcancerpatients
AT mohammadfyazdi symptomaticmetastasispredictionwithserialmeasurementsofca153inprimarybreastcancerpatients
AT mehdichamani symptomaticmetastasispredictionwithserialmeasurementsofca153inprimarybreastcancerpatients
_version_ 1725645991868104704